|
Leveraging expertise developed from his extensive work with HIV, Jackson Laboratory (JAX) Professor Derya Unutmaz, M.D., led an effort to develop an assay that determines how well anti-SARS-CoV-2 antibodies are able to neutralize binding with ACE-2, the human receptor for the virus. Using a non-infectious pseudo-virus with the SARS-CoV-2 spike protein on the external membrane, the assay does not require a BSL-3-level biosecurity facility, yet detects the presence of neutralizing antibodies with extremely high sensitivity and specificity. In a pre-print posted on medRxiv, Unutmaz shows that the assay is able to detect neutralizing antibody in patient plasma even at high dilutions, up to a million-fold. Read more |
Novel antibody tests reveal complexity of the immune response to SARS-CoV-2
Related Posts
Bar Harbor approves Jackson Lab’s $33M expansion for rare disease research
The Bar Harbor Planning Board has approved a plan by the Jackson Laboratory to build a 20,000-square-foot expansion to its Rare Disease Translational...
Bigelow lab receives $7 million for algae research, business development
Researchers at Bigelow Laboratory for Ocean Sciences believe algae can make a big splash in the agricultural, aquaculture and pharmaceutical industries,...
Should Maine create a public medical school? UMaine System will study the question
The University of Maine System said this week it will work with a national consultant to study the feasibility of launching the state’s...